| 摘要: |
| 目的:探讨孟鲁司特钠联合布地奈德治疗小儿毛细支气管炎的临床疗效、安全性及其对患儿炎症因子的影响。方法:选取2014年2月至2016年2月我院收治的106例毛细支气管炎患儿,随机分成对照组和观察组各53例。两组患儿均给予祛痰、止咳、平喘、抗感染及抗病毒等常规治疗,对照组在常规治疗基础上加用布地奈德吸入治疗,观察组在对照组治疗的基础上再加用孟鲁司特钠口服治疗,两组疗程均为7 d。治疗1个疗程后观察两组患儿的临床疗效及不良反应发生情况,同时比较两组患儿的咳嗽持续时间、肺部啰音持续时间、喘憋持续时间、住院时间,以及血清嗜酸粒细胞阳离子蛋白(ECP)、白细胞介素-4(IL-4)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平的改善情况。结果:观察组治疗总有效率为92.5%,高于对照组的75.5%,差异有统计学意义(P<0.05);观察组患儿咳嗽持续时间、肺部啰音持续时间、喘憋持续时间及住院时间均短于对照组,差异有统计学意义(P<0.01);治疗后两组患儿血清ECP、IL-4、IL-8 及TNF-α水平均改善,且观察组优于对照组,差异有统计学意义(P<0.05);治疗期间两组患儿均无明显不良反应发生。结论:孟鲁司特钠联合布地奈德治疗小儿毛细支气管炎的临床疗效显著,能显著改善患儿血清ECP、IL-4、IL-8 及TNF-α水平,具有较高的安全性,值得临床推广应用。 |
| 关键词: 孟鲁司特钠 布地奈德 儿童 毛细支气管炎 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2017.06.010 |
|
| 基金项目: |
|
| Montelukast Sodium Combined with Budesonide in the Treatment of Children with Bronchiolitis and Its Impact on Inflammatory Factor |
| Liu Diaoxia, Li Yanqin |
| (Tongchuan Maternal and Child Health Care Center, Shaanxi Province, Shaanxi Tongchuan 727000, China) |
| Abstract: |
| Objective: To investigate the clinical efficacy and safety of montelukast sodium combined with budesonide in the treatment of children with bronchiolitis, and its impact on children with inflammatory factor. Methods: One hundred and six cases of children with bronchiolitis in our hospital from February 2014 to February 2016 were randomly divided into the control group and the observation group, 53 cases in each group. Two groups were given conventional treatment of expectorant, antitussive, antiasthmatic and anti-infection and anti-virus etc., the control group based on those was given budesonide, while the observation group on the basis of the control group was given montelukast sodium, the course of treatment in the two groups for 7 days. Observed and recorded the clinical efficacy, adverse reactions after treatment of one course of treatment in two groups, meanwhile, compared of the duration time of coughing, lung rale, wheeze, and hospitalization, and the improvement of the levels of the serum eosinophils cationic protein (ECP), interleukin-4 (IL-4), interleukin-8 (IL-8), and tumor necrosis factor-α(TNF-α). Results: The total efficacy of the observation group was 92.5%, which was significantly higher than that of 75.5% in the control group, the difference was statistically significant (P<0.05). The duration time of coughing, lung rale, wheeze, and hospitalization in observation group was significantly shorter than those in control group, the differences were statistically significant (P<0.05). At the same time, after treatment, the levels of serum ECP, IL-4, IL-8 and TNF-α in the two groups were significantly improved, and the improvement in observation group was significantly better than the control group, the differences were statistically significant (P<0.05). Among the treatment, the two groups had no obvious adverse reactions. Conclusion: Montelukast sodium combined with budesonide in the treatment of children with bronchiolitis has significant effect, and can significantly improve the levels of serum ECP, IL-4, IL-8, and TNF-α, and has a high safety, it is worth of clinical popularizing and application. |
| Key words: montelukast sodium budesonide children bronchiolitis |
